Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24065813 | 0.87 | KEAP1 (0.44) | KEAP1SMN1; SMN2GNAI3GNAO1GNAI1 | |
| SCHEMBL21981137 | 0.85 | PAOX (0.39) | GNAI3GNAO1GNAI1SIGMAR1TSHR | |
| SCHEMBL19928707 | 0.85 | TSHR (0.38) | SMN1; SMN2GNAI3GNAO1GNAI1TSHR | |
| SCHEMBL20850661 | 0.82 | HRH3 (0.44) | SMN1; SMN2GNAI3GNAO1GNAI1TSHR | |
| SCHEMBL24723682 | 0.81 | HRH3 (0.48) | SMN1; SMN2TSHR | |
| SCHEMBL24723810 | 0.81 | HRH3 (0.48) | SMN1; SMN2TSHR | |
| SCHEMBL19840405 | 0.80 | SMN1; SMN2 (0.48) | KEAP1SMN1; SMN2SIGMAR1CYP2D6ALOX15 | |
| SCHEMBL26940040 | 0.78 | CXCR4 (0.44) | SMN1; SMN2GNAI3GNAO1GNAI1SIGMAR1 | |
| SCHEMBL19407025 | 0.78 | KEAP1 (0.47) | KEAP1SMN1; SMN2SIGMAR1TSHR | |
| SCHEMBL1861653 | 0.78 | KEAP1 (0.54) | KEAP1SMN1; SMN2GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210322575-A1 | LIPID NANOPARTICLE FORMULATIONS COMPRISING LIPIDATED CATIONIC PEPTIDE COMPOUNDS FOR NUCLEIC ACID DELIVERY | NUTCRACKER THERAPEUTICS, INC. (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322575-A1 | LIPID NANOPARTICLE FORMULATIONS COMPRISING LIPIDATED CATIONIC PEPTIDE COMPOUNDS FOR NUCLEIC ACID DELIVERY | PHOSPHO1, PLIN3, CETP | KEAP1 2353/4885SMN1; SMN2 2989/4885GNAI3 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.